Centrient Pharmaceuticals announced that on April 25, 2019, its wholly owned subsidiary, Centrient Pharmaceuticals India Private Limited, filed a lawsuit against Dalas Biotech Limited in the High Court of Delhi in New Delhi, India for patent infringement of Indian Patent Number 247301. This patent, which is owned by Centrient, describes an enzymatic process for preparing amoxicillin trihydrate having a low free water content. By its complaint, Centrient seeks compensation for damages and a permanent injunction to prevent the infringing manufacture, use, sale in India and exportation out of India of Dalas’ active pharmaceutical ingredient containing amoxicillin trihydrate produced by a process that amounts to infringement of Indian Patent No. 247301.
Karl Rotthier, CEO at Centrient said: “After having previously filed patent litigation against Sinopharm Weiqida Pharmaceuticals for patent infringement in India, and the Court granting an injunction since April 2017, Centrient shows that it will continue to rigorously enforce its IP assets worldwide against any additional potential infringers in India or abroad.”
25 February 2019
Ronald Merckx to become new CFO of Centrient Pharmaceuticals
Effective May 6th 2019, Ronald Merckx will be joining Centrient Pharmaceuticals as Chief Financial Officer and member of the Executive Committee and Management Board of Directors.
Bart Welten has decided to leave Centrient Pharmaceuticals for personal reasons to pursue his career outside Centrient Pharmaceuticals.
Until May 6th Victoria Bell will be the Chief Financial Officer ad interim.
19 February 2019
The Delhi High Court in India has issued an injunction, restraining Sinopharm Weiqida from exporting its “Amoxycillin Trihydrate” product to India, as it infringes the patent of Centrient Pharmaceuticals
The High Court also found Sinopharm Weiqida guilty of Contempt of Court for failing to follow the previously granted preliminary injunction order
Centrient Pharmaceuticals (“Centrient”), the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals, announced that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceuticals and Sinopharm India, restricting the export and/or import into India of its active pharmaceutical ingredient (API) amoxicillin trihydrate. In addition, the Delhi High Court also found Sinopharm Weiqida prima facie guilty of contempt of Court for illegally importing amoxicillin active ingredients in contravention of the previously granted preliminary injunction in place in India since April 2017. The Court further found that Sinopharm Weiqida has infringed the patent of Centrient.
Centrient, and its wholly owned subsidiaries, Centrient Pharmaceuticals Netherlands B.V. and Centrient Pharmaceuticals India Pvt. Ltd., announced today that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceutical Co., LTD ("Weiqida") blocking the export, importation and sale of its amoxicillin active ingredient into India. The injunction prevents the importation of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India in any form.
Weiqida was also found in contempt of the Delhi High Court’s original preliminary injunction order, granted in April 2017, through its continued importation and sale of its amoxicillin trihydrate active pharmaceutical ingredient in India. Centrient will seek monetary compensation for the damage sustained by the illegal shipments, in violation of the preliminary injunction since April 2017.
Centrient wishes to put all buyers of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient in India on notice (even if such API transits through India under advanced license) to be aware of the above orders of the Delhi High Court. Centrient shall ensure full compliance of the orders of the Delhi High Court and will notify the Indian Customs Authority and other authorities to seize all future Weiqida amoxicillin shipments at the relevant customs facilities.
Karl Rotthier, CEO at Centrient Pharmaceuticals said: “Centrient holds a world-class intellectual property portfolio relating to our innovative, sustainable and environmentally-friendly amoxicillin technology. We will continue to rigorously defend our Intellectual Property assets worldwide as we continue to invest in our innovative R&D programs directed to enzymatically produced, sustainable antimicrobials and statins. We will continue to supply our customers with reliable, non-infringing, top quality amoxicillin.”
10 December 2018
DSM Sinochem Pharmaceuticals announces its new name - Centrient Pharmaceuticals
The name, resulting from a change in ownership, reflects its role at the centre of modern healthcare
Effective December 10, 2018 Centrient Pharmaceuticals is the new name for DSM Sinochem Pharmaceuticals, the leading manufacturer of beta-lactam antibiotics and a provider of next-generation statins and anti-fungals. The new name has been chosen to reflect the company’s key contribution to modern healthcare, and marks the next phase in its strategic evolution following a change of ownership to Bain Capital Private Equity.
CEO Karl Rotthier states: “Our bold and creative new name and logo showcase our company as one which prides itself on being at the centre of modern healthcare, through our life-saving active pharmaceutical ingredients and finished dosage forms. We’re building on a rich history that began 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, then Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Now as Centrient Pharmaceuticals, we have an amazing opportunity to build a strong and differentiated brand in the generic pharmaceutical industry.”
Rotthier continues: “The name Centrient emphasizes the way in which we operate: putting our brand promise of Quality, Reliability and Sustainability at the centre of everything we do. Since the formation of the DSM Sinochem Pharmaceuticals joint venture in 2011, we have grown strongly and consistently. Now as Centrient Pharmaceuticals in partnership with Bain Capital, we are ready for the next phase in our evolution as a global generics pharmaceutical company, able to accelerate the execution of our strategy and grow both organically and through acquisitions.”
Along with the new name, the company will adopt a new logo, corporate brand identity and website. Centrient Pharmaceuticals will provide further updates to customers, suppliers and partners regarding these changes to ensure a smooth transition in the implementation of the new name.
About Centrient Pharmaceuticals
Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms. We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines.
With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2000 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.
Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm.
For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-Mail: firstname.lastname@example.org
31 October 2018
New Ownership for DSP - Sale to Bain Capital completed
Our former shareholders of Royal DSM and the Sinochem Group have now successfully completed the sale of DSP to Bain Capital as of October 31, 2018. This follows the announcement of the transaction on June 29, 2018.With our new shareholder, we at DSP remain committed to our strategy and core values of Quality, Reliability and Sustainability. With their financial, advisory and operational capabilities, combined with extensive knowledge of the healthcare space, Bain Capital will assist us in achieving our vision, and support our strategy and continued growth.
With the successful conclusion of the sale, DSP is now preparing for the launch of our new corporate identity, reflecting this change in ownership as an independent global generics pharmaceutical company. DSP anticipates the launch of our new corporate identity in December 2018. Following this launch, the company will ensure a smooth transition for our customers, suppliers and partners, as we evolve from DSM Sinochem Pharmaceuticals to the new corporate identity.
More information can be found here regarding the completion of sale.
9 August 2018
DSM Sinochem Pharmaceuticals launches Caspofungin finished dosage, its first foray into the anti-fungals portfolio
Sustaining earlier momentum from its successful launches of generic versions of both Rosuvastatin and Atorvastatin earlier in 2018, DSM Sinochem Pharmaceuticals (DSP) has now introduced its generic Caspofungin anti-fungal drug product in the United Kingdom. Additional markets within the EU are scheduled to follow later in the year.
Caspofungin is primarily used in the treatment of invasive candidiasis and aspergillosis, along with other fungal infections. DSP’s generic version is a concentrate powder for infusion solutions, produced in the form of single use vials.
Ongoing portfolio expansion
With the launch now of its first anti-fungal finished dosage formulation, DSP is actively expanding its drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. DSP can now offer finished drug products in statins, anti-fungals and antibiotics across its global network.
Business Unit Director for Drug Products at DSP, Lucas Wiarda stated: “With our third launch of a finished dosage drug product in 2018, I am extremely proud of the team at DSP and the successes we’ve enjoyed this year. Caspofungin is the ideal complement to our product line, which helps to move DSP forward in our goal of producing a full range of finished dosage products for our Active Pharmaceutical Ingredients (APIs). Additionally, with Caspofungin we have a global dossier, allowing us worldwide access for production and sale in the coming years.”
With the introduction of Caspofungin finished dosage formulation into the marketplace, DSP continues to deliver on its brand promise to customers, with Quality via world-class, differentiated active pharmaceutical ingredients, Reliability through a secure supply chain for producing a finished dosage product, and Sustainability at the forefront of its drug product production, using patented enzymatic technology which ensures an unmatched eco-friendly production process.
DSP holds an electronic Common Technical Document (eCTD) dossier for Caspofungin finished dosage formulations (in 50 and 70 mg vials) requiring constant refrigerated storage between 2 and 8 degrees Celsius.
About DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.
Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.
For more information please visit www.dsm-sinochem.com or contact DSM Sinochem Pharmaceuticals Corporate Communications, Geoff Vokes, Senior External Communications Manager. E-Mail: email@example.com
29 June 2018
Bain Capital Private Equity acquires DSM Sinochem Pharmaceuticals2